Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Acalabrutinib has a low risk of sudden death and ventricular arrhythmias in chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL) patients.
MRD guided acalabrutinib, venetoclax and obinutuzumab led to an 88% progression free survival rate in relapsed / refractory chronic lymphocytic leukemia.
Chronic lymphocytic leukemia (CLL) patients do better when their first therapy is acalabrutinib based compared to chemoimmunotherapy.
Acalabrutinib and zanubrutinib have similar excellent efficacy in relapsed or refractory chronic lymphocytic leukemia (CLL).
No new concerns or safety signals were found in old and frail chronic lymphocytic leukemia (CLL) patients treated with acalabrutinib.
Acalabrutinib may be taken alone or in combination with obinutuzumab as a preferred initial (first-line) treatment, or alone as a second- or thirdline treatment.
This real-world study found that patients with chronic lymphocytic leukemia (CLL) treated with first-line acalabrutinib were more likely to need to change therapies or add an additional therapy compared with patients treated with ibrutinib.
Bruton tyrosine kinase (BTK) degraders are a new therapeutic area that might be able to overcome mutations that cause resistance to BTK inhibitors.
Acalabrutinib produced durable responses in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) at higher risk of disease progression.
One click to our most popular content.
